Involvement of the PI3K/Akt/Nrf2 Signaling Pathway in Resveratrol-Mediated Reversal of Drug Resistance in HL-60/ADR Cells

References

• Kim TH, Shin YJ, Won AJ, Lee BM, and Choi WS: Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840, 615–625, 2014. doi:10.1016/j.bbagen.2013.10.023
   PubMed Web of Science ®Google Scholar
• Kim JH, Chen C, and Tony Kong AN: Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Arch Biochem Biophys 512, 160–166, 2011. doi:10.1016/j.abb.2011.06.004
   PubMed Web of Science ®Google Scholar
• Huang F, Wu XN, Chen J, Wang WX, and Lu ZF: Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells. Exp Ther Med 7, 1611–1616, 2014. doi:10.3892/etm.2014.1662
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, et al.: Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44, 591–601, 2011. doi:10.1111/j.1365-2184.2011.00783.x
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, Lu Y, and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4, 988–1004, 2005. doi:10.1038/nrd1902
   PubMed Web of Science ®Google Scholar
• Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, and McCubrey JA: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189–218, 2004. doi:10.1038/sj.leu.2403241
   PubMed Web of Science ®Google Scholar
• Zhang X, Dong W, Zhou H, Li H, Wang N, et al.: α-2,8-Sialyltransferase is involved in the development of multidrug resistance via PI3K/Akt pathway in human chronic myeloid leukemia. IUBMB Life 67, 77–87, 2015. doi:10.1002/iub.1351
   PubMed Web of Science ®Google Scholar
• Yao J, Wei X, and Lu Y: Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells. Biochem Biophys Res Commun 473, 867–873, 2016. doi:10.1016/j.bbrc.2016.03.141
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang Y, Li W, Miao H, Zhang H, et al.: Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochem Pharmacol 92, 220–234, 2014. doi:10.1016/j.bcp.2014.09.008
   PubMed Web of Science ®Google Scholar
• Suzuki T and Yamamoto M: Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med 88, 93–100, 2015. doi:10.1016/j.freeradbiomed.2015.06.006
   PubMed Web of Science ®Google Scholar
• Mercado N, Kizawa Y, Ueda K, Xiong Y, Kimura G, et al.: Activation of transcription factor Nrf2 signalling by the sphingosine kinase inhibitor SKI-II is mediated by the formation of Keap1 dimers. PLoS One 9, e88168, 2014. doi:10.1371/journal.pone.0088168
   PubMed Web of Science ®Google Scholar
• Ji L, Li H, Gao P, Shang G, Zhang DD, et al.: Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One 8, e63404, 2013. doi:10.1371/journal.pone.0063404
   PubMed Web of Science ®Google Scholar
• Lu JF, Pokharel D, and Bebawy M: MRP1 and its role in anticancer drug resistance. Drug Metab Rev 47, 406–419, 2015. doi:10.3109/03602532.2015.1105253
   PubMed Web of Science ®Google Scholar
• Schmitt SM, Stefan K, and Wiese M: Pyrrolopyrimidine derivatives as novel inhibitors of multidrug resistance-associated protein 1 (MRP1, ABCC1). J Med Chem 59, 3018–3033, 2016. doi:10.1021/acs.jmedchem.5b01644
   PubMed Web of Science ®Google Scholar
• Wu L, Li Q, and Liu Y: Polyphyllin D induces apoptosis in K562/A02 cells through G2/M phase arrest. J Pharm Pharmacol 66, 713–721, 2014. doi:10.1111/jphp.12188
   PubMed Web of Science ®Google Scholar
• Rocha G. d G, Oliveira RR, Kaplan MAC, and Gattass CR: 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity. Eur J Pharmacol 741, 140–149, 2014. doi:10.1016/j.ejphar.2014.07.054
   PubMed Web of Science ®Google Scholar
• Ma H, Cheng L, Hao K, Li Y, Song X, et al.: Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1. PLoS One 9, e85113, 2014. doi:10.1371/journal.pone.0085113
   PubMed Web of Science ®Google Scholar
• Wang H, Wang H, Liang J, Jiang Y, Guo Q, et al.: Cell-penetrating apoptotic peptide/p53 DNA nanocomplex as adjuvant therapy for drug-resistant breast cancer. Mol Pharm 11, 3352–3360, 2014. doi:10.1021/mp5001058
   PubMed Web of Science ®Google Scholar
• Sprouse AA and Herbert BS: Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells. Anticancer Res 34, 5363–5374, 2014.
   PubMed Web of Science ®Google Scholar
• Cho S, Lu M, He X, Ee PL, Bhat U, et al.: Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci USA 108, 20778–20783, 2011. doi:10.1073/pnas.1019452108
   PubMed Web of Science ®Google Scholar
• Wang C, Hong Z, and Chen Y: Involvement of p38 MAPK in the drug resistance of refractory epilepsy through the regulation multidrug resistance-associated protein 1. Neurochem Res 40, 1546–1553, 2015. doi:10.1007/s11064-015-1617-y
   PubMed Web of Science ®Google Scholar
• Kweon SH, Song JH, and Kim TS: Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395, 104–110, 2010. doi:10.1016/j.bbrc.2010.03.147
   PubMed Web of Science ®Google Scholar
• Ren Z, Wang L, Cui J, Huoc Z, Xue J, et al.: Resveratrol inhibits NF-kB signaling through suppression of p65 and IκB kinase activities . Pharmazie 68, 689–694, 2013.
   PubMed Web of Science ®Google Scholar
• Huang H, Lin H, Zhang X, and Li J : Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the ells by the NF-κB-dependent pathway . Oncol Rep 27, 2050–2056, 2012.
   PubMed Web of Science ®Google Scholar
• Chen JR, Jia XH, Wang H, Yi YJ, Wang JY, et al.: Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Int J Oncol 48, 2063–2070, 2016. doi:10.3892/ijo.2016.3423
   PubMed Web of Science ®Google Scholar
• Wang H, Jia XH, Chen JR, Wang JY, and Li YJ: Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep 35, 3659–3668, 2016. doi:10.3892/or.2016.4730
   PubMed Web of Science ®Google Scholar
• Song NY, Kim DH, Kim EH, Na HK, and Surh YJ: 15-Deoxy-delta 12, 14-prostaglandin J2 induces upregulation of multidrug resistance-associated protein 1 via Nrf2 activation in human breast cancer cells. Ann NY Acad Sci 1171, 210–216, 2009. doi:10.1111/j.1749-6632.2009.04914.x
   PubMed Web of Science ®Google Scholar
• Udasin RG, Wen X, Bircsak KM, Aleksunes LM, Shakarjian MP, et al.: Nrf2 regulates the sensitivity of mouse keratinocytes to nitrogen mustard via multidrug resistance-associated protein 1 (Mrp1). Toxicol Sci 149, 202–212, 2016. doi:10.1093/toxsci/kfv226
   PubMed Web of Science ®Google Scholar
• Lin M, Hu J, Liu T, Li J, Chen B, et al.: Knockdown of nucleophosmin by RNA interference reverses multidrug resistance in resistant leukemic HL-60 cells. Immunobiology 218, 1147–1154, 2013. doi:10.1016/j.imbio.2013.04.001
   PubMed Web of Science ®Google Scholar